Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

키워드

참고문헌 (17)

1. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
2. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
3. European Association For The Study Of The Liver, "EASL clinical practice guidelines : management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
4. Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
5. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
6. Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
7. Lee JM, "Longterm adefovir dipivoxil monotherapy for up to 5 years in lamivudineresistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
8. Lampertico P, "Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B : from guidelines to field practice", J Hepatol, 50, pp.644~647 (2009)
9. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
10. Chang TT, "A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients", Gastroenterology, 129, pp.1198~1209 (2005)
11. Sherman M, "Entecavir therapy for lamivudine-refractory chronic hepatitis B : improved virologic, biochemical, and serology outcomes through 96weeks", Hepatology, 48, pp.99~108 (2008)
12. Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection", Gastroenterology, 139, pp.1207~1217 (2010)
13. Cho HJ, "Tenofovirbased rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance", J Med Virol, 87, pp.1532~1538 (2015)
14. 이혜원, "Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)", Clinical and Molecular Hepatology, 22(4), pp.443~449 (2016), 대한간학회[DOI]
15. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure : results of a randomised trial", Gut, 65, pp.852~860 (2016)
16. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure : results of a randomised trial", Gut, 65, pp.1045~1051 (2016)
17. Lim YS, "Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B : a 5-year clinical trial", J Hepatol, 71, pp.35~44 (2019)

관련 논문AI추천